Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT04649879

Convalescent Plasma for Treatment of COVID-19

Convalescent Plasma for Treatment of COVID-19: An Open Randomised Controlled Trial

Sponsor: Danderyd Hospital

Conditions Covid19

Interventions SARS-CoV-2 convalescent plasma Standard of care

Updated 4 times since 2021 Last updated: Jan 26, 2022 Started: Dec 3, 2020 Primary completion: Jan 26, 2022 Completion: Jan 26, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04649879, this PHASE2/PHASE3 trial focuses on Covid19 and remains completed. Sponsored by Danderyd Hospital, it has been updated 4 times since 2020, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Mar 2022 — Jul 2024 [monthly]

Completed PHASE2_PHASE3

Status: Not Yet Recruiting → Completed
Jan 2021 — Mar 2022 [monthly]

Not Yet Recruiting PHASE2_PHASE3

First recorded

Dec 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Danderyd Hospital
Falu Hospital
Joakim Dillner
Karolinska Institutet

Data source: Karolinska University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Falun, Sweden
• Stockholm, Sweden